Liver cancer stem cells: Implications for a new therapeutic target

Liver International

Volumn 29, Issue 7, 2009, Pages 955-965

  Lee, Terence Kin Wah ^a   Castilho, Antonia ^a   Ma, Stephanie ^a   Ng, Irene Oi Lin ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bone marrow cells; CSCs; HCC; Hepatocytes; Oval cells

Indexed keywords

ABC TRANSPORTER; BETA CATENIN; CD133 ANTIGEN; CD45 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; IMATINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RETRORSINE; SONIC HEDGEHOG PROTEIN; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

APOPTOSIS; BONE MARROW CELL; CANCER STEM CELL; CELL ACTIVATION; CELL DIVISION; CELL FUNCTION; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CELL THERAPY; CELL TRANSDIFFERENTIATION; CHRONIC HEPATITIS; DISEASE MARKER; DRUG RESISTANCE; GENE EXPRESSION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER REGENERATION; LIVER RESECTION; NONHUMAN; PROTEIN FUNCTION; REVIEW; STEM CELL; TUMOR GROWTH; Y CHROMOSOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG DESIGN; HEPATOCYTES; HUMANS; LIVER; LIVER NEOPLASMS; LIVER REGENERATION; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 67650469849     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02040.x     Document Type: Review

References (116)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008; 58: 71-96.
2. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 2006; 6: 674-87.
3. Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211.
4. El-Serag HB. Hepatocellular carcinoma: An epidemiologic view. J Clin Gastroenterol 2002; 35: 72-8.
5. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-8.
6. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004; 127 (Suppl. 1): S35-50.
7. Anzola M. Hepatocellular carcinoma: Role of hepatitis B and hepatitis C viruses' proteins in hepatocarcinogenesis. J Viral Hepat 2004; 11: 383-93.
8. Benvegnu L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994; 74: 2442-8.
9. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: Old and new paradigms. Gastroenterology 2004; 127: 56-61.
10. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004; 127: 72-8.
11. El-Serag HB, Engels EA, Landgren O, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology 2009; 49: 116-23.
12. Carr BI. Hepatocellular carcinoma: Current management and future trends. Gastroenterology 2004; 127: 218-24.
13. Kassahun WT, Fangmann J, Harm J, Hauss J, Bartels M. Liver resection and transplantation in the management of hepatocellular carcinoma: A review. Exp Clin Transpl 2006; 4: 549-58.
14. Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127: 277-82.
15. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 1999; 30: 1434-40.
16. Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127: 268-76.
17. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
18. Aguayo A, Patt YZ. Nonsurgical treatment of hepatocellular carcinoma. Semin Oncol 2001; 28: 503-13.
19. Kuvshinoff BW, Ota DM. Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery 2002; 132: 605-11.
20. Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B. Hepatocellular carcinoma: Systemic treatments. J Clin Gastroenterol 2002; 35(Suppl. 2): S109-14.
21. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-42.
22. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23: 8093-108.
23. Klonisch T, Wiechec E, Hombach-Klonisch S, et al. Cancer Stem cell markers in common cancers-therapeutic implications. Trends Mol Med 2008; 14: 450-60.
24. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-8.
25. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumor initiating cells. Nature 2004; 432: 396-401.
26. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 2007; 445: 106-10.
27. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-5.
28. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8.
29. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-67.
30. Collin AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51.
31. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65: 9328-37.
32. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-23.
33. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104: 973-8.
34. Theise N, Nimmakalayu M, Gardner R, et al. Liver from bone marrow in humans. Hepatology 2000; 32: 11-6.
35. Alison MR. Liver stem cells: Implications for hepatocarcinogenesis. Stem Cell Rev 2005; 1: 253-60.
36. Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997; 276: 60-6.
37. Fausto N. Liver regeneration and repair: Hepatocytes, progenitor cells, and stem cells. Hepatology 2004; 39: 1477-87.
38. Overturf K, al-Dhalimy M, Ou CN, Finegold M, Grompe M. Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes. Am J Pathol 1997; 151: 1273-80.
39. Gournay J, Auvigne I, Pichard V, et al. In vivo cell lineage analysis during chemical hepatocarcinogenesis in rats using retroviral-mediated gene transfer: Evidence for de-differentiation of mature hepatocytes. Lab Invest 2002; 82: 781-8.
40. Bralet MP, Pichard V, Ferry N. Demonstration of direct lineage between hepatocytes and hepatocytes and hepatocellular carcinoma in diethylnitro-samine treated rats. Hepatology 2002; 36: 623-30.
41. Laconi E, Oren R, Mukhopadhyay DK, et al. Long-term, near-total liver replacement by transplantation of isolated hepatocytes in rats treated with retrorsine. Am J Pathol 1998; 153: 319-29.
42. Avril A, Pichard V, Bralet MP, Ferry N. Mature hepatocytes are the source of small hepatocyte-like progenitor cells in the retrorsine model of liver injury. J Hepatol 2004; 41: 737-43.
43. Nowak MA, Bonhoeffer S, Hill AM, et al. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93: 4398-402.
44. Donato MF, Arosio E, Monti V, et al. Proliferating cell nuclear antigen assessed by a computer-assisted image analysis system in patients with chronic viral hepatitis and cirrhosis. Dig Liver Dis 2002; 34: 197-203.
45. Freeman A, Hamid S, Morris L, et al. Improved detection of hepatocyte proliferation using antibody to the pre-replication complex: An association with hepatic fibrosis and viral replication in chronic hepatitis C virus infection. J Viral Hepat 2003; 10: 345-50.
46. Falkowski O, An HJ, Ianus IA, et al. Regeneration of hepatocyte 'buds' in cirrhosis from intrabiliary stem cells. J Hepatol 2003; 39: 357-64.
47. Marshall A, Rushbrook S, Davies SE, et al. Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection. Gastroenterology 2005; 128: 33-42.
48. Marrero JA. Hepatocellular carcinoma. Curr Opin Gastroenterol 2005; 21: 308-12.
49. Libbrecht L, De Vos R, Cassiman D, et al. Hepatic progenitor cells in hepatocellular carcinoma. Am J Surg Pathol 2001; 25: 1388-96.
50. Robrechts C, De Vos R, Van den Heuvel M, et al. Primary liver tumor of intermediate (hepatocyte-bile duct cell) phenotype: A progenitor cell tumor. Liver 1998; 18: 288-93.
51. Kim H, Park C, Han KH, et al. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol 2004; 40: 298-304.
52. Alison MR, Golding M, Sarraf CE, Edwards RJ, Lalani EN. Liver damage in the rat induces hepatocyte stem cells from biliary epithelial cells. Gastroenterology 1996; 110: 1182-90.
53. Roskams T, Desmet V. Ductular reaction and its diagnostic significance. Semin Diagn Pathol 1998; 15: 259-69.
54. Yasui O, Miura N, Terada K, et al. Isolation of oval cells from Long-Evans Cinnamon rats and their transformation into hepatocytes in vivo in the rat liver. Hepatology 1997; 25: 329-34.
55. Wang X, Foster M, AI-Dhalimy M, et al. The origin and liver repopulating capacity of murine oval cells. Proc Natl Acad Sci USA 2003; 100: 11881-8.
56. Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 2005; 25: 16-27.
57. Lowes KN, Brennan BA, Yeoh GC, Olynyk JK. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol 1999; 154: 537-41.
58. Libbrecht L, Desmet V, Van Damme B, Roskams T. Deep intralobular extension of human hepatic 'progenitor cells' correlates with parenchymal inflammation in chronic viral hepatitis: Can 'progenitor cells' migrate? J Pathol 2000; 192: 373-8.
59. Yin L, Lynch D, Sell S. Participation of different cell types in the restitutive response of the liver to periportal injury induced by allyl alcohol. J Hepatol 1999; 32: 497-507.
60. Petersen BE, Bowen WC, Patrene HK, et al. Bone marrow as a potential source of hepatic oval cells. Science 1999; 284: 1168-70.
61. Theise ND, Nimmakayalu M, Gardner R, et al. Liver from bone marrow in humans. Hepatology 2000; 32: 11-6.
62. Ferrari G, Cusella-De Angelis G, Coletta M, et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279: 1528-30.
63. Alison MR, Poulsom R, Jeffery R, et al. Hepatocytes from non-hepatic adult stem cells. Nature 2000; 406: 257.
64. Vance EA, Soiffer RJ, McDonald GB, et al. Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon. Transplantation 1996; 62: 1358-60.
65. Lagasse E, Connors H, AI-Dhalimy M, et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000; 6: 1229-34.
66. Kanazawa Y, Verma IM. Little evidence of bone marrow-derived hepatocytes in the replacement of injured liver. Proc Natl Acad Sci USA 2003; 100: 11850-3.
67. Willenbring H, Bailey AS, Foster M, et al. Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. Nat Med 2004; 10: 744-8.
68. Thorgeirsson SS, Grisham JW. Hematopoietic cells as hepatocyte stem cells: A critical review of the evidence. Hepatology 2006; 43: 2-8 (review).
69. Williams GM, Gebhardt R, Sirma H, Stenback F. Non-linearity of neoplastic conversion induced in rat liver by low exposures to diethylnitrosamine. Carcinogenesis 1993; 14: 2149-56.
70. Tatematsu M, Nagamine Y, Farber E. Redifferentiation as a basis for remodeling of carcinogen-induced hepatocyte nodules to normal appear liver. Cancer Res 1983; 43: 5049-58.
71. Dumble ML, Croager EJ, Yeoh GC, Quail EA. Generation and characterization of p53 null transformed hepatic progenitor cells: Oval cells give rise to hepatocellular carcinoma. Carcinogenesis 2002; 23: 435-45.
72. Ishikawa H, Nakao K, Matsumoto K, et al. Bone marrow engraftment in a rodent model of chemical carcinogenesis but no role in the histogenesis of hepatocellular carcinoma. Gut 2004; 53: 884-9.
73. Wu XZ, Chen D. Origin of hepatocellular carcinoma: Role of stem cells. J Gastroenterol Hepatol 2006; 21: 1093-8.
74. Wicha MS, Liu S, Dontu G. Cancer stem cells: An old idea - a paradigm shift. Cancer Res 2006; 66: 1883-90.
75. Taniguchi H, Chiba T. Stem cells and cancer in the liver. Dis Markers 2008; 24: 223-9 (review).
76. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132: 2542-56.
77. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008; 27: 1749-58.
78. Song W, Li H, Tao K, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008; 62: 1212-8.
79. Salnikov AV, Kusumawidjaja G, Rausch V, et al. Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett 2008; 275: 185-93.
80. Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153-66.
81. Dan YY, Riehle KJ, Lazaro C, et al. Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci USA 2006; 103: 9912-7.
82. Cho RW, Wang X, Diehn M, et al. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 2008; 26: 364-71.
83. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
84. Yang ZF, Ngai P, Ho DW, et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008; 47: 919-28.
85. Yamashita T, Forgues M, Wang W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008; 68: 1451-61.
86. Schmelzer E, Wauthier E, Reid LM. The phenotypes of pluripotent human hepatic progenitors. Stem Cells 2006; 24: 1852-8.
87. Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 2007; 67: 10831-9.
88. Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012-24.
89. Yang W, Yan HX, Chen L, et al. Wnt/β-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 2008; 68: 4287-95.
90. Chiba T, Kita K, Zheng YW, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006; 44: 240-51.
91. Shi GM, Xu Y, Fan J, et al. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol 2008; 134: 1155-63.
92. Siegel A. Moving targets in hepatocellular carcinoma: Hepatic progenitor cells as novel targets for tyrosine kinase inhibitors. Gastroenterology 2008; 135: 733-5.
93. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12: 410-6.
94. Becker G, Schmitt-Graeff A, Ertelt V, Blum HE, Allgaier HP. CD117 (c-kit) expression in human hepatocellular carcinoma. Clin Oncol (R Coll Radiol) 2007; 19: 204-8.
95. Chung CY, Yeh KT, Hsu NC, et al. Expression of c-kit protooncogene in human hepatocellular carcinoma. Cancer Lett 2005; 217: 231-6.
96. Knight B, Tirnitz-Parker J, Olynyk J. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver formation in mice. Gastroenterology 2008; 135: 969-79.
97. Lin AY, Fisher GA, So S, Tang C, Levitt L. Phase II study of imatinib in unresectable hepatocellular carcinoma. Am J Clin Oncol 2008; 31: 84-8.
98. Eckel F, von Dellius S, Mayr M, et al. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology 2005; 69: 363-71.
99. Ma S, Chan KW, Lee TK, et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 2008; 6: 1146-53.
100. Smith LM, Nesterova A, Ryan MC, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008; 99: 100-9.
101. Inagawa S, Itabashi M, Adachi S, et al. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: Correlation with tumor progression and postoperative survival. Clin Cancer Res 2002; 8: 450-6.
102. Seng G, Apte U, Cieply B, Singh S, Monga SP. siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia 2007; 9: 951-9.
103. Sicklick JK, Li YX, Jayaraman A, et al. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 2006; 27: 748-57.
104. Wang Q, Huang S, Yang L, et al. Down-regulation of Sonic hedgehog signaling pathway activity is involved in 5-fluorouracil-induced apoptosis and motility inhibition in Hep3B cells. Acta Biochim Biophys Sin 2008; 40: 819-29.
105. Gramantieri L, Giovannini C, Lanzi A, et al. Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int 2007; 27: 997-1007.
106. Qi R, An H, Yu Y, et al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 2003; 63: 8323-9.
107. Rountree CB, Ding W, He L, Stiles B. Expansion of CD133 expressing liver cancer stem cells in liver specific PTEN deleted mice. Stem Cells 2009; 27: 290-9.
108. Tang Y, Kitisin K, Jogunoori W, et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci USA 2008; 105: 2445-50.
109. Chiba T, Miyagi S, Saraya A, et al. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res 2008; 68: 7742-9.
110. Wang H, Pan K, Zhang HK, et al. Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 134: 535-41.
111. Wakamatsu T, Nakahashi Y, Hachimine D, Seki T, Okazaki K. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol 2007; 31: 1465-72.
112. Hu C, Li H, Li J, et al. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 2008; 29: 2289-97.
113. Folmer Y, Schneider M, Blum HE, Hafkemeyer P. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs. Cancer Gene Ther 2007; 14: 875-84.
114. Kawamata H, Tachibana M, Fujimori T, Imai Y. Differentiation-inducing therapy for solid tumors. Curr Pharm Des 2006; 12: 379-85.
115. Livraghi T, Meloni F, Frosi A, et al. Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma: An open randomized clinical trial. Oncol Res 2005; 15: 399-408.
116. Yin C, Lin Y, Zhang X, et al. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. Hepatology 2008; 48: 1528-39.